SG11201803913RA - Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain - Google Patents

Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Info

Publication number
SG11201803913RA
SG11201803913RA SG11201803913RA SG11201803913RA SG11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA SG 11201803913R A SG11201803913R A SG 11201803913RA
Authority
SG
Singapore
Prior art keywords
international
opioid
oxide derivative
pct
cambridgeshire
Prior art date
Application number
SG11201803913RA
Inventor
Steve Whitelock
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SG11201803913RA publication Critical patent/SG11201803913RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, -, Organization IIIM1411011101010111110101111 1010111111111110111001101011111110111011# International Bureau ... ...... .Y1 j ..... ...,/ (10) International Publication Number International Publication Date WO 2017/085502 Al 26 May 2017(26.05.2017) WIPO I PCT (51) (21) (22) (25) (26) (30) (71) (71) (72) (74) International Patent Classification: A61K 9/70 (2006.01) A61P A61K 31/485 (2006.01) International Application Number: International Filing Date: Filing Language: Publication Language: Priority Data: 1520390.4 19 November 2015 Applicant: EURO-CELTIQUE Jean Piret, L-2350 Luxembourg (LU). Applicant (for SD only): GORDON, C/O Marks & Clerk LLP, 62-68 Cambridgeshire CB2 1LA (GB). 18 November (81) Designated States (unless otherwise indicated, for every 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/GB2016/053600 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 2016 (18.11.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (19.11.2015) GB (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, S.A. [LU/LU]; 1, me GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Kirsteen [GB/GB]; DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Hills Road, Cambridge LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Mundipharma Research GW, KM, ML, MR, NE, SN, TD, TG). Park, Milton Road, Cam- (GB). Published: with international search report (Art. 21(3)) LLP; 62-68 Hills Road, 1LA (GB). Inventor: WHITELOCK, Steve; Limited, 191 Cambridge Science bridge Cambridgeshire CB4 OGW Agent: MARKS & CLERK Cambridge Cambridgeshire CB2 = Title: ABUSE RESISTANT TRANSDERMAL NON-TRANSDERMALLY DELIVERED 32 ----)2i : The present invention provides a transdermal delivery device comprising comprises a N-oxide derivative (54) N composition DELIVERY DEVICES AND COMPOSITIONS N-OXIDE DERIVATIVE OF AN OPIOID ANTAGONIST 34 32 31 33 COMPRISING AN OPIOID AGONIST AND FOR THE TREATMENT OF PAIN 30 / 35 a pharmaceutical composition, wherein said an opioid agonist or salt thereof. - A V' eek( 1) 1 V i)' az, co 'D V (> el ° a V J . . g a ',' a 1 7 a ‘) to O ci- (.•_, 0 el. 0 1-1 ei © ir) ir) ot 0 IN Il 0 (57) C ,////// Z/Z/Z/Z. - \ Figure 4 of an opioid antagonist, or a salt thereof, and
SG11201803913RA 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain SG11201803913RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1520390.4A GB201520390D0 (en) 2015-11-19 2015-11-19 Composition
PCT/GB2016/053600 WO2017085502A1 (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Publications (1)

Publication Number Publication Date
SG11201803913RA true SG11201803913RA (en) 2018-06-28

Family

ID=55133015

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803913RA SG11201803913RA (en) 2015-11-19 2016-11-18 Abuse resistant transdermal delivery devices and compositions comprising an opioid agonist and a non-transdermally delivered n-oxide derivative of an opioid antagonist for the treatment of pain

Country Status (14)

Country Link
US (1) US20180344726A1 (en)
EP (1) EP3377048B1 (en)
JP (1) JP2018534319A (en)
KR (1) KR20180074797A (en)
CN (1) CN108601747A (en)
AU (1) AU2016355113A1 (en)
BR (1) BR112018009886A2 (en)
CA (1) CA3005775A1 (en)
ES (1) ES2799516T3 (en)
GB (1) GB201520390D0 (en)
IL (1) IL259457A (en)
MX (1) MX2018006157A (en)
SG (1) SG11201803913RA (en)
WO (1) WO2017085502A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722928A (en) * 1985-12-02 1988-02-02 E. I. Du Pont De Nemours And Company N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes
EP2092936B1 (en) * 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
GB0026137D0 (en) * 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20040033255A1 (en) * 2002-06-10 2004-02-19 Baker Carl J. Transdermal delivery device disposal system
NZ549576A (en) * 2004-02-23 2010-04-30 Euro Celtique Sa Abuse resistance opioid transdermal delivery device using microspheres of opiate antagonist
JP2010510326A (en) * 2006-11-22 2010-04-02 プロジェニックス ファーマスーティカルス インコーポレーテッド N-oxides of 4,5-epoxy-morphinanium analogs
WO2009067275A1 (en) * 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
CA2718943A1 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
WO2011009020A2 (en) * 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
JP2013523780A (en) * 2010-04-02 2013-06-17 オールトランツ インコーポレイティド Abuse deterrent transdermal preparations of opiate agonists and agonist-antagonists

Also Published As

Publication number Publication date
MX2018006157A (en) 2019-04-04
AU2016355113A1 (en) 2018-05-24
CA3005775A1 (en) 2017-05-26
IL259457A (en) 2018-07-31
WO2017085502A1 (en) 2017-05-26
ES2799516T3 (en) 2020-12-18
EP3377048B1 (en) 2020-04-22
GB201520390D0 (en) 2016-01-06
JP2018534319A (en) 2018-11-22
CN108601747A (en) 2018-09-28
US20180344726A1 (en) 2018-12-06
KR20180074797A (en) 2018-07-03
EP3377048A1 (en) 2018-09-26
BR112018009886A2 (en) 2018-11-13

Similar Documents

Publication Publication Date Title
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201804934PA (en) Novel Compounds
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201408279QA (en) Social sharing of security information in a group
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201806623VA (en) Bacteria over-expressing c-di-amp and therapeutic methods
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones